JNJ Stock Recent News
JNJ LATEST HEADLINES
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
The healthcare titan unveiled its first set of quarterly results for 2024. It missed slightly on the top line but beat on profitability.
The Investment Committee discuss some big movers in the market today.
Johnson & Johnson (J&J) has emphasized the pivotal role of medical technology (MedTech) in advancing healthcare. During a Tuesday (April 16) call with analysts to discuss the first quarter (Q1) and full-year 2023 financial results, the pharmaceutical giant underscored its commitment to bolstering its reputation as an “innovation powerhouse.
CFRA views the newly announced $13.1B Johnson & Johnson (JNJ) shockwave deal as positive. David Toung and Sel Hardy discuss the takeaways from Johnson & Johnson's earnings.
J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.
Johnson & Johnson (NYSE:JNJ) reported better-than-expected first quarter profits driven by strong sales of its cancer drugs, but shares of the pharma giant traded lower as revenue narrowly missed estimates. For Q1, the company reported that its adjusted earnings per share (EPS) increased by 12.4% to $2.71, topping estimates of $2.64.
The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Johnson & Johnson (JNJ) posted a mixed first-quarter earnings Tuesday, and raised its dividend while narrowing full-year guidance for 2024.
Shares of Johnson & Johnson NYSE: JNJ are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face.